Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 850 of 1463 entries
View as:

The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients

Phase: N/A Priority: Normal
NCT ID: NCT02747979 Org: User:
Start: 04/30/09 End: 05/31/10 Due: 05/31/11

Information, Networks and Rewards to Optimise Adherence to Diabetic Services

Phase: N/A Priority: Normal
NCT ID: NCT03804970 Org: User:
Start: 08/15/19 End: 12/30/20 Due: 12/30/21

Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00677118 Org: User:
Start: 06/30/06 End: 03/31/15 Due: 03/31/16

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT01288664 Org: User:
Start: 01/31/11 End: 12/31/12 Due: 12/31/13

Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02958111 Org: User:
Start: 01/31/17 End: 12/31/23 Due: 12/31/24

South China Prospective Cohort Study of Chronic Disease

Phase: N/A Priority: Normal
NCT ID: NCT02917317 Org: User:
Start: 05/01/17 End: 12/31/20 Due: 12/31/21

Trabeculectomy Versus Peripheral Iridectomy Plus Goniotomy in Advanced PACG

Phase: N/A Priority: Normal
NCT ID: NCT05163951 Org: User:
Start: 01/05/22 End: 06/30/26 Due: 06/30/27

A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT02629757 Org: User:
Start: 04/30/15 End: 05/31/23 Due: 05/31/24

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Phase: N/A Priority: Normal
NCT ID: NCT04586088 Org: User:
Start: 05/05/20 End: 09/05/23 Due: 09/05/24

Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01818973 Org: User:
Start: 03/31/13 End: 03/31/20 Due: 03/31/21

EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02714010 Org: User:
Start: 08/31/15 End: 12/31/22 Due: 12/31/23

Guangzhou Nutrition and Health Study (GNHS)

Phase: N/A Priority: Normal
NCT ID: NCT03179657 Org: User:
Start: 07/01/08 End: 12/31/27 Due: 12/31/28

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06900218 Org: User:
Start: 05/01/25 End: 05/01/33 Due: 05/01/34

Artificial Intelligence-assisted Screening of Malignant Pigmented Tumors on the Ocular Surface

Phase: N/A Priority: Normal
NCT ID: NCT05645341 Org: User:
Start: 12/05/22 End: 06/05/23 Due: 06/05/24

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04606108 Org: User:
Start: 10/19/20 End: 03/19/24 Due: 03/19/25

Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial

Phase: N/A Priority: Normal
NCT ID: NCT05531916 Org: User:
Start: 11/21/22 End: 12/31/24 Due: 12/31/25

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06900647 Org: User:
Start: 01/01/25 End: 06/30/28 Due: 06/30/29

Maintenance Treatment With Capecitabine in Colorectal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02027363 Org: User:
Start: 01/31/10 End: 06/30/14 Due: 06/30/15

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT04021992 Org: User:
Start: 07/15/19 End: 12/15/23 Due: 12/15/24

Cluster Randomized Controlled Screening Trial for NPC

Phase: N/A Priority: Normal
NCT ID: NCT00941538 Org: User:
Start: 01/31/08 End: 12/31/23 Due: 12/31/24

Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab

Phase: N/A Priority: Normal
NCT ID: NCT03973138 Org: User:
Start: 01/01/15 End: 01/01/20 Due: 01/01/21

Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein

Phase: N/A Priority: Normal
NCT ID: NCT00993941 Org: User:
Start: 10/31/09 End: 04/30/11 Due: 04/30/12

Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02002416 Org: User:
Start: 01/31/06 End: 12/31/14 Due: 12/31/15

Multi-model Image of Doxycycline in TAO

Phase: N/A Priority: Normal
NCT ID: NCT05112211 Org: User:
Start: 01/01/22 End: 12/01/26 Due: 12/01/27

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04365049 Org: User:
Start: 04/01/20 End: 12/31/23 Due: 12/31/24